Activation of Melatonin Signaling Promotes β-Cell Survival and Function

Safia Costes, Marti Boss, Anthony P. Thomas, and Aleksey V. Matveyenko

Type 2 diabetes mellitus (T2DM) is characterized by pancreatic islet failure due to loss of β-cell secretory function and mass. Studies have identified a link between a variance in the gene encoding melatonin (MT) receptor 2, T2DM, and impaired insulin secretion. This genetic linkage raises the question whether MT signaling plays a role in regulation of β-cell function and survival in T2DM. To address this postulate, we used INS 832/13 cells to test whether activation of MT signaling attenuates proteotoxicity-induced β-cell apoptosis and through which molecular mechanism. We also used nondiabetic and T2DM human islets to test the potential of MT signaling to attenuate deleterious effects of glucotoxicity and T2DM on β-cell function. MT signaling in β-cells (with duration designed to mimic typical nightly exposure) significantly enhanced activation of the cAMP-dependent signal transduction pathway and attenuated proteotoxicity-induced β-cell apoptosis evidenced by reduced caspase-3 cleavage (−40%), decreased activation of stress-activated protein kinase/Jun-amino-terminal kinase (−50%) and diminished oxidative stress response. Activation of MT signaling in human islets was shown to restore glucose-stimulated insulin secretion in islets exposed to chronic hyperglycemia as well as in T2DM islets. Our data suggest that β-cell MT signaling is important for the regulation of β-cell survival and function and implies a preventative and therapeutic potential for preservation of β-cell mass and function in T2DM. (Molecular Endocrinology 29: 682–692, 2015)
animal models of T2DM also report impaired nocturnal MT secretion upon induction of hyperglycemia (9, 10). This apparent reduction in nocturnal MT secretion is associated with a decreased pineal gland size, loss of MT production, and up-regulation of inhibitory α-adrenoceptors (10). Taken together, loss of MT secretion in T2DM further supports a potential role of MT in pathophysiology of T2DM. This premise is supported by a recent observation demonstrating that loss of nocturnal MT secretion is associated with a higher risk of developing T2DM (11).

Diurnal activation of MT receptor signaling is implicated in the regulation of organisms’ circadian rhythms and entrainment of circadian clocks, an observation recently extended to β-cells (12). In addition to its known circadian functions, MT signaling is also involved in the regulation of diverse physiological processes, including metabolic control (13, 14). MT’s actions are mediated by two high-affinity Gi/o receptors (MT-1 and MT-2) with transduction pathways exhibiting a classic Gi-coupled receptor pattern of activation (15). Importantly, the MT receptor transduction pathway varies based on the duration of exposure to MT, i.e., acute (minutes) vs persistent (hours). This distinction is particularly important, given that physiological exposure of cells to MT occurs throughout the duration of the dark phase of the circadian cycle (16). Studies show that acute exposure to MT inhibits adenylate cyclase (AC) activity and attenuates cAMP production leading to decreased activation of downstream targets such as protein kinase A (PKA) and cAMP responsive element binding protein (CREB) (15). On the other hand, persistent activation of the MT receptor leads to sensitization and enhancement of AC activity and increased activation of the cAMP-PKA-CREB cascade (17), phenomenon shown to be present in β-cells (18).

Given increased insights into the importance of MT receptor signaling in pathophysiology of T2DM, we hypothesized that the persistent activation of MT signaling (with duration intentionally designed to recapitulate typical nightly exposure to MT) will be beneficial for the regulation of β-cell function and survival in T2DM. To address this hypothesis, we used INS 832/13 cells and isolated human islets from control and T2DM patients to explore the potential of β-cell MT signaling to enhance activation of the cAMP-PKA-CREB pathway and enhance β-cell survival and β-cell secretory function in the context of molecular stress associated with T2DM.

Materials and Methods

Cell culture

The rat insulinoma cell line INS 832/13 was kindly provided by Dr C. Newgard (Duke University, Durham, NC). INS 832/13 cells were grown in RPMI 1640 medium supplemented with 10 mM HEPES, 1 mM sodium pyruvate, 100 IU/mL penicillin, and 100 mg/mL streptomycin (Invitrogen), 10% heat-inactivated fetal bovine serum (Gemini), and 50 mM β-mercaptoethanol (Sigma) at 37°C in a humidified 5% CO2 atmosphere.

For acute stimulation experiments (see Figure 2A), INS 832/13 cells plated in six-well dishes (70% confluence) were cultured overnight (12–14 hours) in serum-free RPMI 1640 medium containing 2.8 mM glucose, 10 mM HEPES, 1 mM pyruvate, 200 U/mL penicillin, 100 μg/mL streptomycin, and 0.1% BSA (fatty acid free, low endotoxin [Sigma; A8806]) in the presence of MT (Bachem; 1, 10, or 100 nM) diluted in dimethylsulfoxide (DMSO; Sigma), MT receptor agonist ramelteon (LG Pharma; 1 nM) diluted in DMSO (Sigma), or vehicle solution (DMSO; Sigma). DMSO vehicle treatment was administered to all (non-MT/ramelteon) conditions to correct for potential confounding effects of DMSO, which was used to prepare the MT/ramelteon solutions. Cells were subsequently exposed for 10 minutes to serum-free RPMI 1640 medium containing 2.8 mM glucose (basal conditions), 10 nM glucagon-like peptide 1 (GLP-1; Sigma), or 100 nM gastric inhibitory polypeptide (GIP; Tocris Bioscience) at 16.7 mM glucose.

For adenovirus transduction experiments (see Figure 3A), INS 832/13 cells were plated on six-well plates at the density of 10⁶ cells/well and cultured for 24 hours. Cells were transduced with human islet amyloid polypeptide (h-IAPP) adenovirus at 400 multiplicity of infection (MOI) in complete RPMI 1640 medium for 48 hours. MT (10 nM) was added during the last 12–14 hours. At the end of the experiment, cells were washed with cold PBS and lysed for 10 minutes at 4°C in Nonidet P-40 lysis buffer [0.5% Nonidet P-40; 20 mM Tris-HCl, pH 7.5; 150 mM NaCl; 2 mM MgCl₂; 1 mM dithiothreitol; 5 mM NaF; 1 mM Na₃VO₄; and protease inhibitors (Sigma)] and centrifuged at 10,000 rpm for 10 minutes to remove insoluble materials. Supernatant was stored at −20°C until use for the subsequent protein determination by bicinchoninic assay (Bio-Rad Laboratories) and Western blotting.

Immunofluorescent staining

Cells were plated on coverslips in 12-well dishes and allowed to reach approximately 40% confluence. Cells were incubated for 48 hours in standard RPMI 1640 culture medium as described above. Cells were then treated with 10 nM MT for 1 hour at 37°C. After rinsing with PBS, cells were fixed with 4% PFA for 30 minutes at room temperature (RT), soaked in soaking buffer (Tris buffered saline and 2% Triton X-100) for 20–30 minutes at RT. Blocking was performed using blocking buffer (3% BSA and 1% Triton X-100) for 2 hours at RT. Cells on coverslips or pancreatic sections were stained with a goat anti-MT-2 antibody (1:50; Santa Cruz Biotechnology) and guinea pig anti-insulin antibody (1:100; Invitrogen) and then mounted with Vectashield with 4’,6’-diamino-2-phenylindole (Vector Laboratories) and viewed using Leica DM6000 microscope (Leica Microsystem). Images were acquired using OpenLab software (Improvision).

Western blotting

Proteins (25–40 μg/lane) were separated on a 4%–12% Bis-Tris NuPAGE gel and blotted onto a polyvinylidene fluoride membrane (FluoroTrans; VWR). Membranes were probed
overnight at 4°C with primary antibodies. Antiphospho-CREB antibody (which detects CREB when phosphorylated at serine 133), antiphospho-ERK1/2 (which selectively recognizes the doubly phosphorylated active forms of these kinases, Thr202/Tyr204), anticleaved caspase-3, antiphospho-stress-activated protein kinase/Jun-amino-terminal kinase (JNK) (Thr183/Tyr185), and antiguyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were purchased from Cell Signaling. Horseradish peroxidase-conjugated secondary antibodies were from Invitrogen. Proteins were visualized by enhanced chemiluminescence (Millipore), and protein expression levels were quantified using the Labworks software (UVP).

Detection of protein modification by Oxyblot

For the OxyBlot preparation, 5 μL of cell or islet lysates (~15 μg of protein) obtained as previously described were mixed with 5 μL of 12% sodium dodecyl sulfate. Samples were then treated with 10 μL of 2,4-dinitrophenylhydrazine (DNPH) solution or 10 μL of control derivatization solution and incubated at room temperature for 15 minutes, after which 7.5 μL of neutralization solution was added. Proteins were then separated on a 4%–12% Bis-Tris NuPAGE gel and transferred onto a polyvinylidene fluoride membrane (FluoroTrans; VWR), and the membrane was blocked in 1% BSA for 1 hour. The membrane was incubated overnight with a primary antibody (rabbit anti-DNPH; Millipore) and then for 1 hour at room temperature with horseradish peroxidase-conjugated secondary antibody (goat antirabbit; Millipore). Proteins were visualized by enhanced chemiluminescence (Millipore), and the protein expression levels were quantified using the Labworks software (UVP) using GAPDH as loading control.

Targeted PCR arrays

INS 832/13 cells were transduced with h-IAPP adenovirus at 400 MOI in complete RPMI 1640 medium for 48 hours as previously described with MT (10 nM) or vehicle (DMSO) added during the last 12–14 hours. Subsequently, cells were homogenized using QIAshredder microcentrifuge spin-columns (79654; QIAGEN), and total RNA isolation was performed using the RNeasy mini kit (74104; QIAGEN) according to manufacturer’s instructions. RNA abundance was quantified using the NanoDrop 1000 spectrophotometer (NanoDrop Technologies), and cDNA was synthesized from 0.5 μg total RNA using the RT2 first-strand kit (330520; QIAGEN) according to the manufacturer’s instructions. The following targeted PCR arrays were performed in 96-well format using the RT2 SYBR Green quantitative PCR master mix (330520; QIAGEN) and the QuantStudio 6 Flex real-time PCR system (Applied Biosystems) according to the manufacturer’s instructions: rat apoptosis RT2 Profiler PCR array (PARN-012ZC-2; QIAGEN) and the rat oxidative stress RT2 profiler PCR array (PARN-065ZC-2; QIAGEN). Free web-based RT2 Profiler PCR Array Data Analysis Software (version 3.5; SABiosciences) was used to determine δΔcycle threshold based fold-changes in expression of target genes using standardized settings (ie, baseline, threshold) and β-actin as the endogenous control gene across all plates.

Human islets

Nondiabetic (n = 5 shipments) and T2DM human islets (n = 4 shipments) were obtained through the Integrated Islet Distri-

bution Program (Supplemental Table 1) and maintained in RPMI 1640 medium with 5 mM glucose and 10% fetal bovine serum at 37°C. Insulin secretion was assessed by static incubation at basal (5 mM glucose per 30 minutes) and hyperglycemic conditions (25 mM glucose per 30 minutes) or GLP-1 stimulation (10 nM, 30 minutes) with insulin measured by ELISA (ALPCO). GSIS and OxyBlot analysis in nondiabetic islets were assessed after an exposure to four conditions: 1) 72 hours’ incubation in RPMI 1640 with 5 mM glucose (control), 2) 72 hours in 25 mM glucose (glucotoxicity model), 3) 72 hours in 25 mM glucose with 100 nM MT (for the final 12–14 hours), and 4) 72 hours in 25 mM glucose with 1 nM ramelteon (for the final 12–14 hours) (see Figure 5A). GSIS in T2DM islets was assessed after an overnight incubation (12–14 hours) in the presence of MT (100 nM), MT receptor agonist ramelteon (1 nM), or vehicle solution (DMSO) (see Figure 6A).

Statistical analysis

Results expressed as the means ± SEM for n independent experiments, as indicated in figure legends. Statistical analyses were carried out by a Student’s t test. A value of P < .05 was taken as evidence of statistical significance.

Results

MT receptor activation potentiates cAMP/PKA/CREB pathway in β-cells

Consistent with previous reports, we confirmed robust MT receptor expression in human and rodent β-cells as well as in INS 832/13 cells used in the current study (Figure 1). Acute exposure of β-cells to MT (10 nM) led to MT-2 internalization (Figure 1), consistent with the kinetics of MT receptor activation.

We next investigated whether persistent overnight exposure to MT potentiates activation of CREB and ERK1/2 pathways (Figure 2 and Supplemental Figure 1), both known to play important roles in the regulation of β-cell function and survival (19–21). Exposure to MT (in concentrations ranges 1–100 nM for 12–14 hours) led to the enhancement of CREB activation (phosphorylation of serine 133), particularly evident at 10 nM MT concentrations (1–100 nM for 12–14 hours) (see Figure 5A). GSIS in T2DM islets was assessed after an overnight incubation (12–14 hours) in the presence of MT (100 nM), MT receptor agonist ramelteon (1 nM), or vehicle solution (DMSO) (see Figure 6A).
MT receptor activation promotes β-cell survival in a cell model of proteotoxicity

We next examined whether pretreatment of β-cells with MT promotes β-cell survival in T2DM. We transduced INS 832/13 cells with adenovirus expressing h-IAPP, a cell model of β-cell apoptosis that recapitulates molecular features of β-cell demise in patients with T2DM (ie, induction of endoplasmic reticulum and oxidative stress [22]). As expected, cells overexpressing h-IAPP exhibited robust β-cell apoptosis associated with induction of caspase-3 cleavage, activation/phosphorylation of JNK (stress activated protein kinase/Jun-amino-terminal kinase) at threonine 183 and tyrosine 185 (Figure 3, B and C), and induction of oxidative stress assessed by detection of oxidatively modified proteins (Figure 3D). MT exposure (10 nM, 12–14 hours) blunted h-IAPP-induced β-cell apoptosis evidenced by reduced caspase-3 cleavage (∼40% vs vehicle, \( P < .05 \), Figure 3, B and C, \( n = 5 \)) and reduced phosphorylation of JNK (∼50% vs vehicle, \( P = .055 \), Figure 3, B and C, \( n = 3 \)). Furthermore, MT treatment also decreased proteotoxicity-associated oxidative stress (∼50% vs vehicle, \( P < .05 \), Figure 3D and Supplemental Figure 2, \( n = 5 \)). The experiments conducted with INS 832/13 cells overexpressing the nonamyloidogenic rodent IAPP ascertained that MT receptor activation decreases the toxicity associated with the amyloidogenic properties of h-IAPP rather than just protein overload (Supplemental Figure 3).

To delineate putative transcriptional targets of MT signaling in β-cells, we used INS 832/13 cells with adenovirus-expressing cytotoxic h-IAPP exposed (12–14 hours) to either vehicle (DMSO) or MT (10 nM) treatment and subsequently assessed approximately 150 genes known to mediate cellular apoptosis or oxidative stress pathways (Figure 4). Most notably, the activation of MT signaling resulted in a significant reduction in Caspase 12 (0.27 ± 0.02-fold vs vehicle, \( P < .05 \), \( n = 3 \)) and Caspase 4 (0.57 ± 0.04-fold vs vehicle, \( P < .05 \), \( n = 3 \)) mRNA expression, purported mediators of β-cell loss in diabetes (22) (Figure 4A). Also, activation of MT signaling reduced mRNA expression of cellular mediators of reactive oxygen species production and oxidative stress response such as Ncf1 (p47phox) (0.50 ± 0.04-fold vs vehicle, \( P < .05 \), Figure 4B, \( n = 3 \)) and Ptgs2 (Cox-2) (0.42 ± 0.12-fold vs vehicle, \( P < .05 \), \( n = 3 \)), genes known to promote β-cell failure (23, 24). In addition, MT treatment also increased mRNA expression of Nox4 (1.9 ± 0.23-fold vs vehicle, \( P = .058 \), Figure 4B, \( n = 3 \)), a gene shown to enhance β-cell functionality (25).

MT receptor activation promotes β-cell function in human islets

We next tested the potential of MT receptor activation to mitigate β-cell dysfunction in human islets (see Supplementary Table 1 for islet donor information). To induce β-cell dysfunction characteristic of T2DM, we first ex-
posed isolated human islets to chronic hyperglycemia (72 hours at 25 mM glucose), a condition associated with decreased CREB expression (26), induction of oxidative stress (27), and loss of GSIS (28). Chronic hyperglycemia led to the induction of oxidative stress and loss of glucose and incretin-stimulated insulin secretion (Figure 5, B–D). MT as well as MT receptor agonist pretreatment (12–14 hours) resulted in a significant improvement in oxidative stress as well as partial restoration of glucose-stimulated (P < .05, basal vs glucose-stimulated for MT and MT receptor agonist, Figure 5C, n = 5) and incretin-stimulated (P < .05, basal vs GLP-1 stimulated for MT receptor agonist, Figure 5D, n = 5) insulin response. Finally, we studied β-cell function in cadaveric islets obtained from patients with T2DM, which demonstrated a decline in glucose- (P = .2 for basal vs glucose stimulated, Figure 6B, n = 4) and incretin-stimulated insulin responsiveness (P = .1 for basal vs GLP-1-stimulated, Figure 6C, n = 4). Activation of MT receptor signaling was beneficial in restoring GSIS in islets from patients with T2DM (P < .05, basal vs glucose stimulated for MT pretreatment, Figure 6B, n = 4), but failed to show significant improvement for incretin-mediated insulin release (Figure 6C, n = 4).

Discussion

A variant in MTNR1B (gene encoding MT-2 receptor) is associated with impaired MT receptor signaling and consequent increased susceptibility for T2DM (29), raising a postulate that MT receptor signaling is involved in the regulation of glucose control. Importantly, the association between the MTNR1B variant and T2DM is attributed to β-cell failure rather than alteration in insulin sensitivity or body size (6, 30, 31). In particular, in a recent study of 43 single-nucleotide polymorphisms associated with T2DM, the MTNR1B variant displayed the strongest effect on diminished insulin secretion and disposition index during an oral glucose tolerance test (7). Given that β-cell failure is essential to the onset of T2DM, in the current study, we tested whether activation of MT signaling in vitro is beneficial for the preservation of β-cell function and survival in the context of molecular stress associated with T2DM. We report that MT signaling has the potential to attenuate proteotoxicity-induced β-cell apoptosis and improve deleterious consequences of glucotoxicity and T2DM on insulin secretion and oxidative stress in human islets.

A role for MT in the regulation of glucose homeostasis and β-cell health was proposed decades ago (32), an ob-
servation supported by a number of recent studies (8, 11, 13, 33, 34). Pinealectomized rodents develop diurnal hyperglycemia, impaired glucose tolerance, and loss of GSIS (33, 34). These deleterious metabolic effects of pinealectomy are presumably mediated due to the loss of tissue MT signaling because a majority of these effects are reversed by nightly MT supplementation (33). Interestingly, MT levels are reduced in humans with T2DM (and rodent models of diabetes), whereas nondiabetic individuals exhibiting low nightly MT secretion appear to be at an increased risk of developing diabetes (8, 11). Whether a progressive loss of MT secretion and signaling in humans contributes to the induction of \( \beta \)-cell failure and predisposition to T2DM remains to be explored; however, our current data provide further support for the functional link between \( \beta \)-cell MT receptor signaling and regulation of \( \beta \)-cell survival and function in T2DM.

Activation of MT receptor signaling (with duration designed to mimic the period of darkness i.e., > 8 hours) has been shown to sensitize cAMP-dependent signal transduction pathway, particularly by potentiating PKA and CREB activation, a phenomenon shown to be present in pancreatic \( \beta \)-cells (15, 18). The ability of MT to potentiate the cAMP-dependent signal transduction pathway is important for MT’s ability to regulate circadian rhythms and clock gene expression (12, 35) and also appears to contribute to regulation of \( \beta \)-cell function and survival in human islets. Previous work has shown that adequate PKA activity is essential for the stimulation of acute insulin response to glucose (19, 21). Moreover, CREB expression is essential for maintaining proper \( \beta \)-cell mass, function, and protection against \( \beta \)-cell apoptosis (21). Mice deficient in CREB expression develop diabetes characterized by reduced \( \beta \)-cell mass and increased \( \beta \)-cell apoptosis (36). Furthermore, expression of a CREB dominant-negative mutant in isolated human islets leads to increased \( \beta \)-cell apoptosis, whereas overexpression of CREB reverses \( \beta \)-cell apoptosis by raising Bcl-2 levels (26).
Interestingly, MTNR1B variants characterized by impaired cAMP-dependent signaling display increased association with T2DM, whereas a variant with a loss of ERK1/2 signaling (another pathway activated by MT signaling) did not demonstrate an association with T2DM risk (29).

Further studies are needed to delineate the exact molecular transduction pathways responsible for the beneficial effects of MT signaling on β-cell function and survival.

To assess the potential transcriptional targets responsible for beneficial effects of MT signaling on the β-cell,

---

**Figure 4.** Persistent activation of β-cell MT receptor signaling modulates apoptotic and oxidative stress gene expression in response to β-cell proteotoxicity. Apoptosis RT² Profiler PCR (A) and oxidative stress RT² Profiler PCR (B) arrays demonstrating relative mRNA expression of 146 genes purported to mediate cellular apoptotic and oxidative stress pathways in INS 832/13 cells transduced with h-IAPP adenovirus for 48 hours and exposed to either MT (10 nM) or vehicle (DMSO). The graph represents mRNA levels expressed as fold change for MT (10 nM) vs vehicle (DMSO)-treated cells (n = 3 independent experiments for each array). Data are expressed as mean ± SEM. Dashed red line represents mRNA expression in vehicle (DMSO)-treated cells. Genes demonstrating notably significant changes vs vehicle are highlighted in red. DMSO vehicle treatment was administered to all non-MT conditions to correct for potential confounding effects of DMSO, which was used to prepare MT solutions.
we used a cell model of β-cell failure due to h-IAPP-induced proteotoxicity (37–39). Importantly, this cell model recapitulates key molecular features of β-cell failure in T2DM, particularly the induction of endoplasmic reticulum and oxidative stress (40). Because MT signaling has been previously shown to attenuate the cellular apoptotic program and reduce oxidative burden (41), we performed targeted PCR arrays to examine effects of MT signaling on expression of nearly 150 genes purported to mediate apoptotic and oxidative stress pathways (Figure 4). Apoptotic array data revealed significantly attenuated mRNA expression of proapoptotic caspases-3, -4, and -12 in response to MT treatment, consistent with the antiapoptotic effects of MT signaling on the β-cell (Figure 4A). Importantly, a nearly 70% reduction in Caspase-12 expression is particularly notable, given that an increase in β-cell caspase-12 expression is a feature of T2DM (22, 42).

Oxidative stress array data also revealed intriguing biological targets of β-cell MT signaling (Figure 4B). Activation of MT signaling resulted in a substantial reduction in Ncf1 (also known as p47phox) expression, which encodes an activating subunit of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes. Ncf1-dependent NOX activation is an important determinant of cellular reactive oxygen species accumulation and consequent induction of oxidative stress (43). Interestingly, the deletion of Ncf1 results in the attenuation of hyperglycemia-induced oxidative stress and β-cell dysfunction in a mouse model of diabetes (23). Moreover, the activation of MT signaling also led to a significant decline in prostaglandin-endoperoxidase synthase 2 (Ptgs2, also known as Cox-2) mRNA. Induction of Ptgs2 expression, which occurs in response to a number of proinflammatory and prooxidative stimuli in β-cells, leads to increased prostaglandin E2 biosynthesis, which acts as a potent inhibitor
of β-cell function (24). Importantly, the inhibition of Ptgs2 gene expression has been shown to enhance β-cell function and attenuate the deleterious effects of prooxidative stressors on the β-cell (44). Taken together, further studies are needed to delineate the exact signaling pathways linking MT receptor activation with downstream transcriptional targets. In that context, a number of described genes have been shown to contain cAMP responsive elements in their promoter regions (45, 46).

In our human islet studies, prolonged exposure to hyperglycemia resulted in elevated basal insulin secretion and the subsequent inability to further elevate insulin secretion in response to a glucose challenge, an observation consistent with previous reports (28). The mechanisms underlying this observation appear to be related to changes in genetic β-cell programming (dedifferentiation), likely implemented to defend against ensuing oxidative damage (47). Subsequently, a number of typically repressed genes (eg, MCT1, LDHA, and HK1) have been shown to be up-regulated, and β-cell identity genes (PDX-1, Mafa, and NKX6.1) be suppressed in β-cells exposed to prolonged hyperglycemia and/or oxidative stress (47, 48). This metabolic switch favors glycolytic over oxidative metabolism and results in the stimulation of ATP production and insulin secretion at basal glucose levels and the consequent failure to further enhance ATP production and insulin secretion after a glucose challenge (49). How does the activation of MT signaling reverse increased basal insulin secretion and partially restore glucose-stimulated insulin release in glucotoxic islets? One plausible hypothesis will be through the attenuation of oxidative stress, which will likely result in a diminution of β-cell dedifferentiation as recently described by Guo et al (48).

Another potential mechanism by which MT signaling may regulate β-cell function and survival is through the modulation of circadian clock gene expression. Accumulating evidence suggests that the functional β-cell circadian clock is essential for proper β-cell function and survival as well as maintenance of normal glucose homeostasis (50–52). Indeed, disrupting the β-cell circadian clock either via genetic manipulation or exposure to circadian misalignment in vivo leads to a loss of insulin secretion, diminished β-cell growth, and increased susceptibility to oxidative stress and β-cell apoptosis (50–53). Diurnal activation of MT receptor signaling has been shown to modulate clock gene expression (eg, Per-1) in the pituitary (54) and the pancreas (55) in vivo as well as potentiate clock gene expression in cultured β-cells (12). It is unknown whether the beneficial effects of MT on the
β-cell observed in our study are attributed to improved β-cell circadian clock function; however, it is important to point out that islets isolated from T2DM patients appear to exhibit disrupted clock gene expression patterns (56). Further work is needed to understand the role of MT receptor signaling in the control of β-cell circadian clock function.

In conclusion, our data demonstrates that the persistent activation of MT signaling in vitro has the potential to attenuate β-cell loss and dysfunction associated with molecular stress present in T2DM. This work provides further support for the functional link between MT receptor signaling and regulation of β-cell survival and function in T2DM and suggests that chronic activation of MT signaling presents a potential preventative and treatment strategy to preserve β-cell mass and function in T2DM.

Acknowledgments

We are grateful to Kevin Hsu (University of California, Los Angeles) for excellent technical support. We also thank Dr Peter C. Butler and Dr Christopher S. Colwell (University of California, Los Angeles) for their helpful discussions and insightful comments.

Address all correspondence and requests for reprints to: Aleksey V. Matveyenko, PhD, Mayo Clinic School of Medicine, Mayo Clinic, 200 First Street SW, Rochester MN 55905. E-mail: matveyenko.aleksey@mayo.edu.

This work was supported by Grant R01DK098468 from the National Institutes of Health and an investigator-initiated grant from Takeda Pharmaceuticals (to A.V.M.). S.C. was supported by Grant 2012-D-001-SUP from the Larry L. Hillblom Foundation.

Disclosure Summary: The authors have nothing to disclose.

References


